Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Interim Report, January – March 2021

Good sales growth and strategic acquistion in SwedenJanuary - March 2021 · Revenues increased by 6 percent to SEK 894 (844) million. · Adjusted EBITA decreased by 2 percent and amounted to SEK 41.6 (42.6) million, corresponding to an adjusted EBITA margin of 4.7 (5.1) percent. · Profit before tax amounted to SEK 30.8 (33.4) million. · Profit after tax amounted to SEK 22.5 (25.8) million. · Profit per share amounted to SEK 2.47 (2.85). · New contracts relating to cloud services worth SEK 78 (51) million were contracted, an increase by 53 percent. · Proact topped the

NENT Group’s first Estonian Viaplay Original is ‘Who Shot Otto Mueller?’

· Jaan Rekkor, Tambet Tuisk and Märt Avandi lead all-star Estonian cast · Crime drama is directed by René Vilbre and scripted by Birk Rohelend · ‘Who Shot Otto Mueller?’ will premiere exclusively on Viaplay An unprecedented line-up of Estonia’s top creative talents will partner with Nordic Entertainment Group (NENT Group), the Nordic region’s leading streaming company, to create the first-ever Estonian Viaplay Original. Helmed by award-winning director René Vilbre and written by Birk Rohelend, the tense crime drama ‘Who Shot Otto Mueller?’ stars Jaan Rekkor, Tambet Tuisk and Märt

Rottneros interim report January-March

Rising prices and strong demand for market pulp· SOLD VOLUME was 112,0 (110,0) thousand tonnes due to strong demand for market pulp.  · PRODUCED VOLUME was 102,5 (109,4) thousand tonnes. It was mainly the cold winter that had a negative impact on production.  · THE CORONA PANDEMIC entails continued measures to minimise the risk of spreading the infection in the Group’s facilities. Production was not affected by the pandemic during the quarter. However, the development at Packaging has been delayed.  · NET TURNOVER decreased by 7 percent to 542 (585) MSEK. The higher list

Alimak Group: Interim report January – March 2021

Margin improvements · Currency translation effects had negative impact on reported order intake, revenue and earnings · Organic order intake growth of 7% · Revenue flat organically as expected due to incoming order backlog and continued effects of the COVID-19 pandemic · Margin improvements in all divisions and cost savings programme on track · Strong Cash Flow and further strengthened financial position First quarter · Order intake increased by 1% to MSEK 1,073 (1,067) with an organic increase of 7% · Revenue decreased by 8% to MSEK 846 (916) with an organic

Hansa Biopharma interim report Jan-Mar 2021

First commercial sales of Idefirix[®] recorded in Q1; New preclinical collaboration with argenx; Encouraging three-year follow-up data in kidney transplantationLund, Sweden April 22, 2021 Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and interim report for January – March, 2021. Highlights for the first quarter 2021 · First commercial sales of  Idefirix[®] recorded in Q1 2021 following treatment of the first patients. Commercial launch activities in early launch countries continue to be carried

Interim report January–March 2021: Recovery and good profitability

First quarter: · Sales amounted to SEK 379 (334) million, corresponding to an increase of 14 percent in SEK. Sales increased by 20 percent in local currency. · Operating income before depreciation and amortisation (EBITDA) amounted to SEK 163 (116) million, corresponding to a margin of 43 (35) percent. Fluctuations in exchange rates negatively impacted EBITDA by SEK 10 million. · Net income amounted to SEK 119 (80) million, which gave earnings per share of SEK 1.09 (0.74). Gothenburg, April 22, 2021VITROLIFE AB (publ)Thomas Axelsson, CEO

Interim Report January-March 2021

First quarter · Order intake amounted to SEK 1,027 (1,432) million, a decline of 28 percent · Net sales increased 75 percent to SEK 1,291 (736) million. Based on constant exchange rates the increase was 88 percent · EBIT increased to SEK 498 (55) million and EBIT margin was 39 (8) percent  · Earnings per share were SEK 3.99 (0.40) “We delivered a stable start to the year. We continue to focus on helping our customers address the challenges still being created by the pandemic. We delivered growth of 75 percent and the EBIT margin improved to 39 percent, which was largely

Robin Boheman new CEO of Instalco

Robin Boheman, CFO of Instalco, has been appointed new CEO of the company. Robin will assume the position on 1 September 2021.Robin Boheman was one of the first employees in Instalco after CEO Per Sjöstrand and has been part of the Group management team since the start. Robin worked as Head of M&A and Business Development between 2014-19 and was appointed as CFO of the group in 2019. He has prior experience of strategy development in listed companies and he has also worked as a consultant. He holds a MSc in accounting and finance from Uppsala University. ”Ever since he was employed,

Interim report January-March 2021

A positive start to the yearQuarter 1, 2021 · Incoming orders amounted to SEK 1,035m (995), equivalent to a currency-neutral growth of 14.7 percent compared with the same period last year. Compared with the final quarter 2020, incoming orders increased by 12.7 percent. · Net sales amounted to SEK 868m (981), equivalent to a currency-neutral decrease of of 2.7 percent compared with the same period last year. · Operating profit was SEK 87.2m (64.2), giving an operating margin of 10.0 percent (6.5). · Adjusted operating profit was SEK 87.4m (65.1), giving an adjusted operating

Progress in establishing reference centers within digital pathology

STOCKHOLM – April 22, 2021 – ContextVision, a medical technology software company specializing in image processing, image analysis and decision support tools for digital pathology, today reports its first quarter results for 2021. The quarter saw strong and promising progress within digital pathology and the company’s first product, INIFY Prostate Screening. While the ongoing pandemic slowed sales slightly, solid financials – paired with close dialogues with present and prospective clients – provide a positive outlook. “Dr. Filippo Fraggetta – one of the leading pathologists in Europe

Aveny Ögonklinik expands on Gothenburg’s most fashionable street

Aveny Ögonklinik is growing by 540 square metres at Kungsportsavenyen 33. Previous retail space on the second floor is now being reconstructed to become office space and a reception for the expanding eye clinic.“We have increasing demand from our patients and at the same time a new and more comprehensive agreement with the Västra Götaland Regional Council, so it feels fantastic to be able to expand our floor space after the reconstruction. Creating the best patient experience is something that we give high priority to – excellent premises, accessibility and a really good location are worth

Wärtsilä to start the repurchase of its own shares

Wärtsilä Corporation, stock exchange release, 22 April 2021 at 08:45 AM EESTWärtsilä to start the repurchase of its own shares  The Board of Directors of Wärtsilä Corporation has decided to use the authorisation given by the Annual General Meeting held on 4 March 2021 to repurchase the company’s own shares. The maximum number of shares to be repurchased in one or more instalments is 1,700,000 shares, corresponding to approximately 0.29% of the total number of the company’s shares, which is 591,723,390. The shares will be repurchased using the company’s unrestricted equity. The shares

Interim Report for Duni AB (publ) January 1–March 31, 2021

Continued strong impact from restrictions, preparations for easingJanuary 1–March 31 · Net sales amounted to SEK 932 m (1,249), corresponding to an 25.4% decrease in sales. Adjusted for exchange rate movements, net sales decreased by 22.9%. · Earnings per share after dilution amounted to SEK -1.11 (0.43). · The performance of both sales and income for Q1 are directly related to the social restrictions. · The Duni business area is well prepared to meet the increase in demand expected as social restrictions are eased. · Operating income for the BioPak business area nearly

Gränges upgrades 2025 sustainability targets

Sustainability is a strong driver and enabler of Gränges’ long-term competitiveness and value creation. In March 2019, Gränges launched sustainability targets to 2025 and since then good progress has been achieved towards many of these. To reflect the stronger than anticipated development in the sustainability performance as well as to meet the increased interest and expectations from customers and other stakeholders, Gränges is now upgrading selected sustainability targets. The targets demonstrate Gränges’ efforts to further integrate sustainability across the company and the value chain,

EQT AB (publ) Q1 announcement 2021

CEO COMMENT – FIRST QUARTER 2021It was a busy first quarter - EQT teamed up with Exeter, creating a leader in thematic value-add  real estate investments, fundraising for EQT IX wasmaterially concluded, EQT Infrastructure V had its first close and we set the target size for the EQT Growth fund. In addition, preparations continued for EQT’s potential new strategies and initiatives. Christian Sinding,CEO and Managing Partner  HIGHLIGHTS DURING THE FIRST QUARTER 2021 · EQT signed an agreement to acquire Exeter Property Group and the combination was completed, as announced

Wärtsilä’s Interim Financial Report January–March 2021

Wärtsilä Corporation, Interim Financial Report January–March 2021, 22 April 2021 at 8:30 a.m. local timeWärtsilä’s Interim Financial Report January–March 2021  ORDER INTAKE STABLE, BUT COVID-19 CONTINUES TO BURDEN NET SALES AND PROFITABILITY  This release is a summary of Wärtsilä’s Interim Report January–March 2021. The complete report is attached to this release as a pdf file. It is also available on the company website at www.wartsila.com.  HIGHLIGHTS OF JANUARY–MARCH 2021  · Order intake was stable at EUR 1,244 million (1,247)  · Order book at the end of the period

Munters interim report Jan-Mar 2021 - "Solid first quarter with improved market conditions"

January - March 2021: · In general, market conditions improved. The major effect from the Covid-19 pandemic was increased costs from shortages in the supply chain that was managed well. · Order intake increased +8%, currency adjusted strong growth of +20%, and net sales increased +3%, currency adjusted +14%. Growth was mainly driven by the battery and pharma sub-segments (part of the industrial segment) in business area AirTech and the swine segment in China in business area FoodTech. Also, Services had good growth. · The adjusted EBITA-margin improved to 12.3% (8.3). The

Gränges’ interim report January–March 2021

New record for sales volume and earnings in first quarter First quarter 2021 · Sales volume increased by 41.0 per cent to 126.7 ktonnes (89.9) and net sales to SEK 4,043 million (3,063). Excluding acquisitions sales volume increased by 14.3 per cent to 102.8 ktonnes and net sales was SEK 3,365 million. · Adjusted operating profit increased to SEK 342 million (210) and adjusted operating profit per tonne was 2.7 kSEK (2.3). Excluding acquisitions, adjusted operating profit increased to SEK 293 million. · Profit for the period increased to SEK 239 million (133) and includes

Organic Sales Growth of 63.2%, EBITDA margin of 36.3% and Positive Operating Cashflow

Financial Highlights · Net sales in Q3 were SEK 8.5m, corresponding to a 63.2% increase compared with the same period in 2020 (SEK 5.2m). Sales growth in Q3 based on constant currency was 70.0% compared with the same period in 2020.  Sales for the rolling twelve months period was SEK 36.3m. · EBITDA of SEK 3.1m (SEK -13.7m) corresponding to an EBITDA margin of 36.3% compared to -261.3% for the comparative period. EBITDA before FX-translation was SEK 0.7m (SEK -16.0m) which is a more accurate reflection of underlying earnings.  · Net profit was SEK 0.9m compared with a loss in the

Brian McGuire resigns as board member of Zutec Holdings AB (publ)

Dublin, Ireland, 22 April 2021 – Zutec Holding AB (publ) (“Zutec" or the “Company”) today announced that Board member Brian McGuire has at his own request chosen to resign from the board of directors to spend more time with his family and other interests. Brian McGuire founded Zutec back in 1999 and has had a fundamental role in the company. The Board thanks him for his solid work efforts. Brian resigns with immediate effect after which the Board will consist of four members. The selection of his replacement will take place at the next Annual General Meeting. For more information,

Skanska signs additional contract for a hospital building project in Orlando, Florida, USA , for USD 87M, about SEK 730M

Skanska has signed an additional contract with Orlando Health, Inc. for the construction of the new Orlando Health Jewett Orthopedic Institute in Orlando, Florida, USA. The contract is worth USD 87M, about SEK 730M, which will be included in the US order bookings for the second quarter 2021.The new 34,500-square-meter institute will include an eight-story hospital that will house 75 inpatient rooms and 10 operating rooms (ORs). An adjoining 6-story medical office building will include two floors of ambulatory suites which will contain an added 12 ORs. The inpatient and outpatient facility

Interim Management Statement 1 January–31 March 2021

CEO Dr Martin Edlund: “The satisfactory results from operations in the Faroe Islands, both in terms of electricity production and the DG100 system's performance in automatic mode, provides the right conditions and significant risk reduction to drive the development of larger power plants and the first commercial farms.”Significant events January–March 2021 · At the beginning of March, Minesto resumed operations with the DG100 power plant in the Faroe Islands. The focus has been on optimising electricity production to grid together with the customer, electricity utility company SEV, and

INTERIM REPORT JANUARY - MARCH 2021

Strong start of the yearFirst quarter 2021 · Net sales increased by 15% to SEK 14,030m (12,208). The organic growth was 24%, changes in exchange rates impacted with -10% and acquisitions with 1%. · Operating income increased by 61% to SEK 2,293m (1,424). The operating margin was 16.3% (11.7). For the rolling 12-month period the operating margin amounted to 12.2% (8.9), excluding items affecting comparability. · Earnings per share after dilution amounted to SEK 2.89 (1.73). · Cash flow from operations and investments was SEK 1,548m (416). Direct operating cash flow was SEK

Q1 2021 interim report January-March

5 year strategy on track – 16% organic sales growth and 25% Viaplay subscriber growth·Viaplay paying subscribers up 25% YoY to 3,147k (2,510) with at least 650k paying subscribers to be added in 2021 ·16% organic sales growth with reported sales of SEK 2,982m (3,370m including SEK 723m contribution from subsequently deconsolidated Viasat Consumer business)  ·33% growth in operating income before associated company income (ACI) and items affecting comparability (IAC) when excluding SEK 96m contribution in Q1 2020 from subsequently deconsolidated Viasat Consumer business ·

There are no items matching the current filter
There are no more items matching the current filter
Back to top